첨단바이오 포커스

국민의 안전과 건강을 지키는 한국의약품안전관리원

홈 > 알림마당 > 뉴스레터 > 첨단바이오 포커스

인쇄
게시글 보기
제목 첨단바이오 포커스 제3호
등록자 hyelin 등록일 2021-03-05 조회수 377


Reference

1. 보건복지부 홈페이지
Available from: http://www.mohw.go.kr/react/al/sal0301vw.jsp?PAR_MENU_ID=04&MENU_ID=0403&page=2&CONT_SEQ=363186
2. 기획재정부 홈페이지
Available from: https://www.moef.go.kr/nw/nes/detailNesDtaView.do?searchBbsId1=MOSFBBS_000000000028&searchNttId1=MOSF_000000000053629&menuNo=4010100
3. 청주시 홈페이지
Available from: https://www.cheongju.go.kr/www/selectBbsNttView.do?key=279&bbsNo=40&nttNo=170406&searchCtgry=&searchCnd=all&searchKrwd=&pageIndex=2&integrDeptCode=
4. 식품의약품안전처 홈페이지
Available from: https://www.mfds.go.kr/brd/m_209/view.do?seq=43410&srchFr=&srchTo=&srchWord=&srchTp=&itm_seq_1=0&itm_seq_2=0&multi_itm_seq=0&company_cd=&company_nm=&page=1
5. “Guidance Agenda: Guidance Documents CBER is Planning to Publish During Calender Year 2021” US FDA. Accessed Feb.2, 2021 Available from:
https://www.fda.gov/vaccines-blood-biologics/biologics-guidances/guidance-agenda-guidance-documents-cber-planning-publish-during-calendar-year-2021
6. “Guidance Document: Human Gene Therapy for Neurodegenerative Diseases” US FDA. Accessed Jan.5, 2021 Available from:
https://www.fda.gov/regulatory-information/search-fda-guidance-documents/human-gene-therapy-neurodegenerative-diseases
7. “Updated Information for Human Cell, Tissue, or Cellular or Tissue-based Product (HCT/P) Establishments Regarding the COVID-19 Pandemic” US FDA. Accessed Jan.4, 2021 Available from:
https://www.fda.gov/vaccines-blood-biologics/safety-availability-biologics/updated-information-human-cell-tissue-or-cellular-or-tissue-based-product-hctp-establishments
8. “Guidance Document: Manufacturing Considerations for Licensed and Investigational Cellular and Gene Therapy Products During COVID-19 Public Health Emergency” US FDA. Accessed Jan.21, 2021 Available from: https://www.fda.gov/regulatory-information/search-fda-guidance-documents/manufacturing-considerations-licensed-and-investigational-cellular-and-gene-therapy-products-during
9. “Organogenesis ReNu® Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation For Osteoarthritis of the Knee” Organogenesis. Accessed Jan.11, 2021 Available from: https://www.globenewswire.com/news-release/2021/01/11/2156376/0/en/Organogenesis-ReNu-Receives-FDA-Regenerative-Medicine-Advanced-Therapy-RMAT-Designation-For-Osteoarthritis-of-the-Knee.html
10. 최선례 기자. “아스텔라스 유전자치료약 ‘AT132’ 임상 금지 해제”, 약업신문(2021.12.29.), 
Available from: http://www.yakup.com/news/index.html?mode=view&cat=16&nid=253017
11. “FDA Lifts Hold on Audentes’ Trial of X-Linked Myotubular Myopathy Drug” Biospace. Accessed Dec 28, 2020. Available from:
https://www.biospace.com/article/fda-lifts-hold-on-audentes-trial-of-x-linked-myotubular-myopathy-drug/?keywords=audentes
12. “Capricor Therapeutics Announces DSMB Recommendation to Continue Phase II INSPIRE Trial” Biospace. Accessed Dec 29, 2020 Available from: https://www.biospace.com/article/capricor-therapeutics-announces-dsmb-recommendation-to-continue-phase-ii-inspire-trial-for-severe-covid-19-patients-trial-assessing-ability-of-capricor-s-cardiac-cell-therapy-cap-1002-to-reduce-the-cytokine-storm-associated-with-severe-covid-19/?keywords=Capricor+Therapeutics+
13. 한서경. 임상시험의 안전성 관리를 위한 Data Safety Monitoring Board (DSMB)의 구성과 역할. 약물역학위해관리학회지 2009;2:26-29
14. “Sarep­ta gene ther­a­py for Duchenne mus­cu­lar dy­s­tro­phy fails on func­tion — rais­ing se­ri­ous ques­tions about all their drugs” Accessed Jan 7, 2021 Available from: https://endpts.com/sarepta-gene-therapy-for-duchenne-muscular-dystrophy-fails-on-function-raising-serious-questions-about-all-their-drugs/
15. “ Committee for Advanced Therapies (CAT): 20-22 January 2021” EMA. Accessed Feb. 1, 2021 Available from: https://www.ema.europa.eu/en/events/committee-advanced-therapies-cat-20-22-january-2021
16.  “Luxturna ” EMA. Accessed Jan. 5, 2021 Available from: https://www.ema.europa.eu/en/medicines/human/EPAR/luxturna
17. “Holoclar” EMA. Accessed Jan. 14, 2021 Available from: https://www.ema.europa.eu/en/medicines/human/EPAR/holoclar
18.  “Zynteglo ” EMA. Accessed Jan. 28, 2021 Available from: https://www.ema.europa.eu/en/medicines/human/EPAR/zynteglo
19. “Strimvelis” EMA. Accessed Jan. 28, 2021 Available from: https://www.ema.europa.eu/en/medicines/human/EPAR/strimvelis
20. “Advanced therapy medicinal products (ATMPs) procedural timetables” EMA. Available from: https://www.ema.europa.eu/en/human-regulatory/marketing-authorisation/submission-dates/procedural-timetables#advanced-therapy-medicinal-products-(atmps)-procedural-timetables-section
21. “What’s new” EMA. Accessed Jan. 2021 Available from:
https://www.ema.europa.eu/en/news-events/whats-new/2021-01
22. “ Human medicines: highlights of 2020” EMA. Accessed Jan. 1, 2021 Available from:
https://www.ema.europa.eu/en/news/human-medicines-highlights-2020
23. “Newsletters-Human medicines highlights” EMA. Available from:
https://www.ema.europa.eu/en/news-events/publications/newsletters#human-medicines-highlights-section
24. 박찬영 기자. “뇌손상 '세포치료제' 임상서 운동기능 개선”, 메디소비자뉴스(2021.01.06.),
Available from: http://www.medisobizanews.com/news/articleView.html?idxno=75494
25. 이주현 기자. “안트로젠, 표피박리증 치료제 日 임상 3상 승인”, 한경 BIO Insight(2021.01.08.),
Available from: https://www.hankyung.com/it/article/202101082234i
26. “24th Next Generation Medical Device and Regenerative Medicine Product Evaluation Index Review Meeting / Medical Device Development Guideline Evaluation Review Committee Joint Review Committee” AMED. Accsesed Jan. 27, 2021 Available from: https://www.amed.go.jp/news/event/20210222.html
27. 한국보건산업진흥원. 첨단바이오의약품 산업백서. 2018.
28. 중소기업청. 바이오 산업[시장] 분석. 2013.
29, 양민후 기자. “바이오의약품 미래 먹거리..정부 지원, 다른나라보다 빈약”, 메디포뉴스(2019.05.11.), Available from: http://medifonews.com/news/article.html?no=146022
30. Naomi Kautz. “To Navigate Global Regulatory Frameworks & Expedited Programs for Gene Therapy Development In The U.S., EU & Japan” cell&gene. Accessed Jan.8, 2021 Available from: https://www.cellandgene.com/doc/to-navigate-global-regulatory-frameworks-expedited-programs-for-gene-therapy-development-in-the-u-s-eu-japan-0001
31. 한국바이오의약품협회. 2019 바이오의약품 글로벌 진출 전략 정보. 2019.12.
32. “Guidance Document: Expedited Programs for Serious Conditions – Drugs and Biologics” US FDA. Accessed May 2014 Available from: https://www.fda.gov/media/86377/download
33. “Guidance Document: Expedited Programs for Regenerative Medicine Therapies for Serious Conditions” US FDA. Accessed Feb 2019 Available from: https://www.fda.gov/media/120267/download
34. “Regenerative Medicine Advanced Therapy Designation” US FDA. Last modifed Jan.5, 2021 Available from:
https://www.fda.gov/vaccines-blood-biologics/cellular-gene-therapy-products/regenerative-medicine-advanced-therapy-designation
35. 박실비아. 미국과 EU의 의약품 신속 개발 및 허가 프로그램의 동향과 쟁점. 약학회지 2017;61(3):147-157
36. Sumimasa N. Flexible and Expedited Regulatory Review Processes for Innovative Medicines and Regenerative MEdical Products in the US, the EU, and Japan. Int. J. Mol. Sci. 2019 Aug
37. 식품의약품안전처 식품의약품안전평가원. 2020년 첨단바이오의약품 허가교육 워크숍
Available from: http://www.nifds.go.kr/brd/m_137/view.do?seq=32875&srchFr=&srchTo=&srchWord=&srchTp=&itm_seq_1=0&itm_seq_2=0&multi_itm_seq=0&company_cd=&company_nm=&page=1
38. 식품의약품안전평가원. 바이오의약품 마중물 사업
Available from: https://www.nifds.go.kr/brd/m_137/list.do
39. 식품의약품안전처. 의약품 안전관리 제1차 종합계획(2020~24년)
Available from: https://www.mfds.go.kr/brd/m_218/view.do?seq=33318&srchFr=&srchTo=&srchWord=&srchTp=&itm_seq_1=0&itm_seq_2=0&multi_itm_seq=0&company_cd=&company_nm=&page=1
40. 「첨단재생의료 및 첨단바이오의약품 안전 및 지원에 관한 법률」(법률 제17472호, 2020.9.12.) 제37조

첨부파일
첨단바이오 포커스 제3호 (21년 3월).pdf [27027544 byte]